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1. Introduction 
The epidermal growth factor receptor (EGFR) is receptor tyrosine kinase (RTK) 
dysregulated in glioblastoma (GBM) through overexpression, mutation or inappropriate 
expression of ligand. Activation of the EGFR by these mechanisms contributes to the 
development and progression of GBM by engaging downstream targets, such as the PI3K 
pathway. The de2-7 EGFR (or EGFRvIII), a naturally occurring mutation of the EGFR 
frequently expressed in GBM, preferentially activates this pathway. Clinical trials with 
EGFR-specific tyrosine kinase inhibitors (TKIs) have been disappointing with very little 
antitumor activity observed. The outcome of controlled clinical trials with EGFR-specific 
antibodies is yet to be reported. Encouraging preclinical and preliminary clinical data 
suggests that the combination of EGFR therapeutics and compounds that target molecules 
downstream of EGFR might have increased efficacy. Finally, the identification of 
biomarkers that predict those patients most likely to respond to EGFR inhibition is 
desperately needed. 
2. Expression of EGFR and its ligands in GBM 
The EGFR is frequently expressed in GBM (Jungbluth et al., 2003), the most common and 
deadly form of malignant brain cancer (DeAngelis, 2001). Extensive co-expression of EGFR 
ligands such as EGF and TGF-┙ has also been reported (Ekstrand et al., 1991), suggesting the 
existence of a robust autocrine loop in many cases of GBM. Furthermore, overexpression of 
the EGFR has been reported in up to 60% of GBM cases depending on the technique used 
(Libermann et al., 1985; Schlegel et al., 1994; Jungbluth et al., 2003), with overexpression 
leading to ligand-independent activation of the receptor (Thomas et al., 2003). The activation 
and subsequent phosphorylation of EGFR stimulates several downstream pathways 
including Ras/MAPK, PI3K/Akt, PLC-gamma and STAT3 (Halatsch et al., 2006; Nakamura, 
2007). All four pathways contribute to the tumorigenicity of GBM, but the PI3K/Akt 
pathway appears to have a central role in the development and maintenance of this cancer 
(Chakravarti et al., 2004). Indeed, inactivation/deletion/mutation of PTEN, an endogenous 
inhibitor of the PI3K pathway, is also a common event in GBM (Rasheed et al., 1997). Of 
note, there is an emerging role for EGFR-mediated activation of STAT3 in the development 
of GBM (Weissenberger et al., 2004; Mizoguchi et al., 2006; Sherry et al., 2009). 
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3. Amplification of the EGFR gene in GBM 
Amplification of the EGFR gene was the first reported genetic alteration in GBM (Libermann 
et al., 1985). Subsequent studies have confirmed that approximately 40% of GBMs display 
amplification of the EGFR gene (Wong et al., 1987). Gene amplification invariably leads to 
overexpression of the EGFR at the cell surface (Wong et al., 1987), although given that 
overexpression of the receptor occurs in 60% of GBMs, gene amplification is not the only 
route to increased expression. The majority of GBMs develop rapidly, without evidence of 
pre-existing malignant lesion, and are known as primary (or de novo) GBMs, while 
secondary GBMs arise from low-grade diffuse astrocytomas or anaplastic astrocytomas 
(Furnari et al., 2007; Ohgaki & Kleihues, 2007). EGFR gene amplification is more commonly 
associated with primary GBMs than secondary GBMs, where it occurs at a frequency of less 
than 10% (Watanabe et al., 1996; Ohgaki & Kleihues, 2007). Overexpressed EGFR not only 
activates in a ligand-independent manner, but shows enhanced signaling through the 
STATs, including STAT3 (Thomas et al., 2003; Pedersen et al., 2005), which in turn can 
induce expression of IL-6. Since IL-6 autocrine loops and amplification of the IL6 gene have 
been reported at high frequency in GBM (Weissenberger et al., 2004; Tchirkov et al., 2007), 
this could be an important, but largely overlooked, consequence of EGFR overexpression.  
Recent studies have shown that GBM can be classified into at least 4 distinct molecular sub-
types; classical, pro-neural, neural and mesenchymal (Brennan et al., 2009; Verhaak et al., 
2010). Pro-neural GBMs largely constitutes the secondary GBMs and therefore does not 
display EGFR amplification and/or overexpression. In contrast nearly all GBM in the 
classical sub-type overexpress EGFR (Verhaak et al., 2010). Furthermore, the GBM specific 
mutation, de2-7 EGFR, is found almost exclusively in the classical sub-type. Neural and 
mesenchymal GBMs have variable levels of EGFR with some showing increased expression 
and others decreased expression. 
4. Mutations of EGFR described in GBM 
Amplification of the EGFR gene in GBM is associated with gene rearrangements. The first 
rearrangement to be described in detail was an extracellular domain (ECD) deletion 
producing a mutant known as the de2-7 EGFR (or EGFRvIII) (Sugawa et al., 1990; Yamazaki 
et al., 1990; Ekstrand et al., 1992; Wong et al., 1992). Several other deletion mutants have 
since been described and categorized (Table 1) (Ekstrand et al., 1992; Frederick et al., 2000). 
Numerous subsequent studies have shown that the most common mutation is the de2-7 
EGFR, occurring in about 50% of cases where the EGFR gene is amplified (Wikstrand et al., 
1998; Frederick et al., 2000; Pedersen et al., 2001). This cancer-specific EGFR mutant has a 
specific deletion between exons 2 and 7 of EGFR (Sugawa et al., 1990). The truncation of 
exons 2–7 leads to the elimination of 267 amino acids from the ECD and the insertion of a 
novel glycine at the fusion junction. This renders the mutant EGFR unable to bind any 
known ligand (Sugawa et al., 1990; Wikstrand et al., 1998; Pedersen et al., 2001). Despite this, 
the de2-7 EGFR is capable of low-level constitutive signaling, which is augmented by the 
mutant receptor’s impaired internalization and downregulation (Nishikawa et al., 1994; 
Schmidt et al., 2003). 
GBM cell lines transfected with the de2-7 EGFR display enhanced tumorigenicity when 
grown as xenografts in nude mice, but only a marginal effect on growth is observed in vitro 
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(Nishikawa et al., 1994). Furthermore, expression of the de2-7 EGFR is consistently lost 
when GBM cell lines are established in vitro using serum, yet is retained if GBM samples are 
implanted and subsequently passaged directly in nude mice (Sarkaria et al., 2007). Taken 
together, this indicates that the de2-7 EGFR contributes primarily to aspects of in vivo 
growth. While the increased tumorigenicity mediated by the de2-7 EGFR is primarily due to 
the receptor’s constitutive tyrosine kinase activity (Huang et al., 1997), attempts to identify 
intracellular molecules and signaling pathways associated with its growth advantage 
remain ongoing. Transfection of the de2-7 EGFR into U87MG human GBM cells results in an 
increase in PI3K activity that is important to the growth advantage mediated by the mutant 
receptor, an observation confirmed by several papers (Moscatello et al., 1998; Li et al., 2004; 
Luwor et al., 2004). U87MG cells transfected with the de2-7 EGFR also co-express wild-type 
(wt) EGFR, a scenario that probably mimics the situation in GBM patients. The significance 
of a possible interaction between the de2-7 EGFR and wtEGFR is not fully known, but it has 
been shown that the de2-7 EGFR can directly activate PI3K in the absence of the wtEGFR in 
non-GBM cell lines (Moscatello et al., 1998). We reported that the de2-7 EGFR and the wt 
EGFR can heterodimerize leading to increased PI3K signaling (Luwor et al., 2004), 
suggesting that an interaction between the mutant and wt receptor could enhance de2-7 
EGFR signaling. One clear consequence of PI3K activation by de2-7 EGFR is the increased 
production of VEGF, both under normoxic and hypoxic conditions (Feldkamp et al., 1999), 
ascribing a pro-angiogenic function to this receptor. 
 
Mutation Frequency (%) Biological Effect 
Δ6–273 30 Ligand-independent, failure to 
down-regulate 
Δ521–603 <10 Unknown 
Δ959–1186 <10 Increased ligand-dependant kinase 
activity 
Δ959–1030 and Δ959-1043 <10 Increased basal activity especially 
Δ959–1030 but responds to ligand  
R84K <5 Increased basal activity but 
responds to ligand 
T239P <5 Increased basal activity but 
responds to ligand 
A265V/D/T <5 Increased basal activity but 
responds to ligand 
G574V <1 Increased basal activity but 
responds to ligand 
Kinase mutation (L861Q) <1 Increased basal activity, failure to 
downregulate 
Table 1. Selected mutations of the EGFR expressed in GBM 
Very recently de2-7 EGFR has been shown to stimulate the production of cytokines, 
including IL-6 and LIF, which signal through the gp130 complex (Inda et al., 2010). 
Importantly these cytokines were shown to activate the wtEGFR when it is overexpressed in 
neighboring GBM cells, through a mechanism involving cross-talk between gp130 and 
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EGFR. Activation of the wtEGFR in this manner leads to enhanced proliferation. Thus, de2-7 
EGFR contributes to the growth of surrounding GBM cells through this field effect. This 
work also shows the functional link between EGFR and IL-6. More generally this indicates 
that the de2-7 EGFR actively contributes to the heterogeneity of GBM by acting indirectly 
with neighboring de2-7 EGFR negative cells (Inda et al., 2010). This hypothesis is entirely 
consistent with the observation that wtEGFR amplification and de2-7 EGFR expression are 
usually seen together. It may also explain why the pronounced growth advantage mediated 
by the de2-7 EGFR does not lead in patients to a homogenous population of cells in patients 
all expressing the receptor. 
Lee et al sequenced the entire EGFR gene in a panel of eight GBM cell lines and 132 GBM 
samples (Table 1) (Lee et al., 2006). Interestingly, they identified a series of missense 
mutations in the ECD of the EGFR expressed in 14% of the GBM samples and 12% of the cell 
lines (Lee et al., 2006). In general, the missense mutations were found to be independent of the 
de2-7 EGFR but were associated with EGFR gene amplification; approximately 60% of samples 
with missense mutations also had EGFR gene amplification. Subsequent studies showed that 
these single amino acid mutations led to ligand-independent activation of the EGFR, and 
unlike the wtEGFR, were transforming in NR6 cells; a variant of mouse 3T3 cells lacking the 
EGFR (Lee et al., 2006). However, unlike the de2-7 EGFR, these mutants could also respond to 
ligand stimulation. Recently, we extended these studies and showed that some of these 
mutations also provide a significant advantage to in vivo growth (Ymer et al., 2011). 
The presence of activating kinase mutations, such as those commonly found in lung cancer 
(Sharma et al., 2007), is extremely rare in GBM, with only one sample displaying this type of 
mutation (Lee et al., 2006). Interestingly, a subsequent analysis of 119 lung cancer samples 
failed to find a single missense mutation in the ECD, although 13% of the samples contained 
kinase domain mutations, as expected (Lee et al., 2006). Thus, mutations of the EGFR in 
GBM appear to cluster in the ECD and lead to ligand independence. Therefore, the lessons 
learned with respect to EGFR therapeutics for the treatment of lung cancer are probably of 
minimal value in the context of GBM. Finally, these mutations further emphasize just how 
frequently the EGFR is perturbed in GBM; in fact, taking into account EGFR autocrine loops, 
activation of the EGFR probably occurs in over 70% of GBMs. 
5. EGFR as a therapeutic target in GBM 
Given that the EGFR is activated or dysregulated in a large percentage of GBM cases it is a 
rational target for therapeutic intervention in this disease. There are two major classes of 
EGFR inhibitors either currently approved or being evaluated for the treatment of various 
cancers; antibodies that target the ECD and small molecule TKIs that target the intracellular 
kinase domain (Marshall, 2006). No specific agent from either class has been approved for 
the treatment of GBM, but as described below, a number of clinical trials have been reported 
or are ongoing.  
5.1 Antibodies directed to the EGFR 
Overexpression of the de2-7 EGFR on the cell surface, the unique junctional peptide created 
by the deletion and the aggressive phenotype associated with this receptor, suggests that 
targeting the de2-7 EGFR with antibodies that are cancer-specific is an attractive therapeutic 
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strategy. In fact, antibodies specific for the de2-7 EGFR have been generated; the monoclonal 
antibodies (mAbs) DH8.3 (Hills et al., 1995), L8A4 and Y10 (Wikstrand et al., 1995) all 
preferentially recognize the unique junctional peptide. DH8.3 and Y10 have been shown to 
specifically target cells expressing the de2-7 EGFR (i.e. they do not bind the wtEGFR) (Hills 
et al., 1995; Wikstrand et al., 1995). Although DH8.3 has been shown to target de2-7 EGFR-
expressing xenografts in vivo (Johns et al., 2002), its efficacy has not been reported. The Y10 
antibody has been shown to have in vivo antitumor activity against murine B16 melanoma 
cells transfected with a murine homolog of the human de2-7 EGFR (Sampson et al., 2000), an 
unusual system for its evaluation since expression of the de2-7 EGFR has not been reported 
in melanoma. Furthermore, the antitumor activity seen was completely dependent on the Fc 
function of the Y10 antibody and not a direct inhibitory effect on de2-7 EGFR signaling 
(Sampson et al., 2000). There have been no reports to date of clinical trials using de2-7 
EGFR-specific antibodies. These antibodies are internalized and could be used for delivery 
of radiotherapy or cytotoxics given their specificity (Foulon et al., 2000), but this approach 
has not been examined clinically. 
Numerous therapeutic antibodies to the wtEGFR have been described and several have 
been used in the context of GBM (Quang & Brady, 2004; Belda-Iniesta et al., 2006). These 
antibodies all function in a similar manner by interacting with the L2 domain of the EGFR 
and inhibiting the binding of ligand. Structural studies with Cetuximab suggest that these 
antibodies also prevent EGFR dimerization, a crucial step in its activation (Li et al., 2005). 
Antibodies directed to the wtEGFR do show antitumor activity in GBM xenograft models 
even when the tumors are grown intracranially (Eller et al., 2002; Perera et al., 2005). 
Furthermore, these antibodies can bind the de2-7 EGFR and can inhibit GBM cells co-
expressing the de2-7 and wtEGFR (Perera et al., 2005). However, the large intratumoral 
pressure found in GBM, the ‘remnants’ of a blood brain barrier (BBB) and the inefficient 
nature of GBM vascularization have all raised concerns about the effective targeting of 
antibodies to GBM following systemic administration. Despite these concerns, three 
antibodies targeting wtEGFR are have been tested in GBM using systemic administration, 
including mAb 425. 131I-mAb 425 has been used in several clinical trials and clearly 
demonstrates targeting to GBM following systemic administration (Quang & Brady, 2004). 
Unfortunately, this antibody is of murine origin and can only be administered on a few 
occasions before immune responses render it ineffective. 
Cetuximab is a chimeric antibody directed to the EGFR that has been approved in several 
human cancers including that of the colon (Moosmann & Heinemann, 2007). There are 
anecdotal reports of this antibody being used for the treatment of GBM, but no rigorously 
controlled studies have been implemented to date (Belda-Iniesta et al., 2006). Preclinical in 
vitro and in vivo studies suggest that cetuximab and related antibodies have significant 
antitumor activity in GBM, encouraging the establishment of a Phase I/II clinical trial 
(Combs et al., 2006). In this trial, cetuximab will be co-administered with a combination of 
temozolomide and radiotherapy, which is the standard of care following initial resection of 
a GBM (Trial Number: NCT00311857). Outcomes from this trial should be reported shortly. 
Recently cetuximab was trialed with a combination with bevacizumab (i.e. avastin) and 
irinotecan but did not increase the efficacy of this combination in GBM patients (Hasselbalch 
et al., 2010). There are several other EGFR-directed antibodies either approved or in 
development including Panitumumab (Rivera et al., 2008); however, there have been no 
reports of their systematic evaluation in GBM. 
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A novel EGFR antibody (mAb 806) was generated against cells expressing the de2-7 EGFR 
but, unexpectedly, was also found to bind to a small proportion of the wtEGFR in GBM 
samples that overexpress the receptor (Jungbluth et al., 2003). mAb 806 does not bind the 
unique junctional peptide found in the de2-7 EGFR; rather, it binds to a short cysteine loop 
on the ECD that is only transiently exposed as the wtEGFR moves from its inactive to active 
conformation (Johns et al., 2004). The loop is constitutively exposed in the de2-7 EGFR, 
consistent with our original desire to generate a de2-7 EGFR-specific antibody. Thus, mAb 
806 reactivity is found only in cells with favorable conditions for receptor activation, such as 
the presence of mutations (e.g. de2-7 EGFR), overexpression of the wt receptor or increased 
presence of EGFR ligands. In the case of EGFR overexpression, there is increased activation 
as a result of ligand-independent EGFR activation and changes in glycosylation (Johns et al., 
2005). These conditions are common in malignant cells but are rare in normal tissues, 
thereby allowing mAb 806 to preferentially target malignancy such as GBM but not normal 
organs such as the liver. Our recent Phase I clinical trial confirmed that a chimeric version of 
mAb 806 did not bind normal tissue and could target GBM following systemic 
administration (Scott et al., 2007). Since mAb 806, unlike Cetuximab, does not target organs 
such as the liver it is easier to deliver a therapeutically relevant dose to the site of the GBM. 
Furthermore, the lack of normal tissue uptake will allow the labeling of mAb 806 with 
cytotoxic compounds or radioisotopes to enhance its already substantial antitumor efficacy 
(Johns et al., 2007). This antibody has been licensed and has re-entered clinical trial. 
5.2 Tyrosine kinase inhibitors that target the EGFR 
TKIs are small molecules that specifically target the kinase domain of tyrosine kinases, 
preventing binding of ATP and subsequent activation (Marshall, 2006). Two EGFR-specific 
TKIs have been approved for the treatment of certain cancers (Mendelsohn & Baselga, 2006), 
while several others are in clinical trials. Similar to EGFR-specific antibodies, these 
compounds have shown antitumor activity in in vitro and in vivo preclinical models 
(Mendelsohn & Baselga, 2006). They are active against both the wtEGFR and the de2-7 
EGFR (Stea et al., 2003; Halatsch et al., 2006; Sarkaria et al., 2007), although they might be 
less effective against the latter, especially if the de2-7 EGFR is expressed in the absence of 
the wtEGFR (Learn et al., 2004). Given that there are fewer concerns with regard to delivery 
of TKIs to the site of GBM when compared with antibodies, the development of these 
reagents for the treatment of GBM is more advanced. In fact, excellent targeting of these 
agents to the site of GBM has been well demonstrated (Hofer et al., 2006; Hegi et al., 2011). 
The two clinically approved EGFR TKIs, erlotinib and gefitinib, have been used as 
monotherapy or in combination with temozolomide and/or radiotherapy in clinical trials of 
GBM patients (Table 2 lists selected Phase II trials). No significant clinical activity has been 
observed for either erlotinib or gefitinib in either primary or recurrent GBM when used as 
monotherapies (Table 2). Surgery, followed by temozolomide/radiotherapy is standard of 
care in primary GBM. The addition or erlotinib to this standard of care has been assessed in 
3 different Phase II trials (Table 2). Two of these trials failed to show any benefit when 
erlotinib was added to standard of care and was associated with significant toxicity (Brown 
et al., 2008; Peereboom et al., 2010). In a third trial however, the authors reported 
encouraging PFS and median survival when compared to their previous studies using other 
agents (Prados et al., 2009). All three studies were conducted in newly diagnosed patients. 
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Why these trials have produced conflicting outcomes is not clear, but a comprehensive 
Phase III study is probably required to finally determine if erlotinib improves standard 
therapy. Overall though the data suggests that erlotinib’s benefits are relatively small at 
best. 
 
Trial 
Patients 
(n) 
Objective 
Response# 
PFS 
Median OS 
(months) 
Gefitinib (single agent, recurrent)     
Rich et al (Rich et al., 2004) 53 0 
13% (6 
months) 
10 
Franceschi et al  
(Franceschi et al., 2007) 
Gefitinib 
(single agent, primary) 
16 0 
12% (6 
months) 
6 
Uhm et al (Uhm et al., 2011) 98 N/A 
17% (12 
months) 
12 
Erlotinib (single agent, recurrent)     
Raizer et al (Raizer et al., 2010) 38 0 
3% (6 
months) 
6 
Erlotinib (plus standard care, 
primary) 
    
Peereboom et al  
(Peereboom et al., 2010) 
27 
5 patients 
remain on 
study 
3 months 
(median) 
9Ϯ 
Prados et al (Prados et al., 2009) 65 N/A 
8 months 
(median) 
19 
Brown et al (Brown et al., 2008) 97 N/A 
7 months 
(median) 
15Ϯ 
Abbreviations: CR, complete response; PR, partial response; N/A not available;  
PFS, progression-free survival; OS, overall survival. *Abstract form only.  
#Excludes stable disease. ϮSignificant toxicity 
Table 2. Selected Phase II clinical trials of EGFR TKI’s in GBM 
A group of GBM patients treated with erlotinib or gefitinib who had responded or failed to 
respond to therapy was analyzed retrospectively to determine factors that might explain the 
different responses (Mellinghoff et al., 2005). The majority of responders expressed the de2-7 
EGFR. Furthermore, loss of PTEN, an endogenous inhibitor of PI3K that leads to reduced 
phosphorylated AKT (Akt), was highly predictive of treatment failure. Not surprisingly, the 
co-expression of de2-7 EGFR and PTEN was predictive of response to EGFR-specific TKI 
therapy. A panel of human GBMs directly established as xenografts in nude mice retains 
expression of de2-7 EGFR in some cases (Sarkaria et al., 2006). This model system also 
confirmed that the presence of de2-7 EGFR and PTEN in a xenograft was predictive of 
response (Sarkaria et al., 2007). The mechanistic reasons for this observation remain 
unknown, but it provides a potential method for screening for patients likely to respond to 
TKI therapy. Finally, none of the current trials have shown a correlation between response 
to EGFR TKIs and EGFR gene amplification (Brown et al., 2008), although one 
immunohistochemical study reported a correlation between response to erlotinib and high 
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expression of EGFR in combination with low levels of pAkt (Haas-Kogan et al., 2005). Once 
again this supports the notion that activated EGFR in the presence of low pAkt may be 
indicative of increased levels of response to EGFR inhibition. 
Recently bevacizumab (i.e. avastin) was approved for the treatment of recurrent GBM. A 
Phase II trial of erlotinib and bevacizumab showed that this combination was adequately 
tolerated, but provided no additional benefit to that seen in other bevacizumab containing 
regimens (Sathornsumetee et al., 2010). mTOR is downstream of the PI3K/Akt pathway and 
therefore represents a therapeutic target in GBM. The combination of sirolimus (a mTor 
inhibitor), and erlotinib has been reported in recurrent GBM patients (Reardon et al., 2010). 
While the combination was well tolerated, it displayed negligible anti-tumor activity.  
6. Future developments 
Both Cetuximab and Panitumumab have been approved for the treatment of colon cancer 
and erlotinib and gefitinib are approved for non-small cell lung cancer (NSCLC), validating 
the EGFR as a genuine therapeutic target (Van den Eynde et al., 2011). Given the 
dysregulation of the EGFR in GBM through the range of mechanisms described above, the 
failure of these agents to show significant anti-tumor activity in this cancer is somewhat 
surprising. The possibility that the BBB is responsible for this lack of activity has been 
conclusively discounted for EGFR TKI’s and appears not to be a factor for anti-EGFR 
antibodies, although formal demonstration of this is still required for antibodies. Future 
research should focus the identification of patients more likely to respond to EGFR 
inhibition and identifying other targeted therapies that might work synergistically with 
EGFR inhibitors. Further classification of GBM into unique molecular sub-types beyond the 
four already described (Verhaak et al., 2010) will hopefully help identify EGFR levels of 
tumor subtypes more likely to respond to EGFR inhibition.  
6.1 Lessons from other cancers 
In NSCLC the sub-set of patients most likely to respond to EGFR TKI’s are those containing 
activating mutations in the kinase domain of EGFR (da Cunha Santos et al., 2011). Significant 
clinical and laboratory evidence suggests that these mutations lead to “oncogenic 
addiction”; the phenomenon whereby a tumor becomes largely dependent on a single 
activated kinase. Interestingly, EGFR amplification is not strongly associated with response 
to TKI’s in NSCLC (De Luca & Normanno, 2010). In contrast, EGFR activation in GBM is 
most often driven by gene amplification and/or mutations found in the ECD domain of the 
receptor (Lee et al., 2006), although a recent report described several c-terminal deleted 
EGFR molecules that are constitutively active (Pines et al., 2010). The clinical data in GBM 
implies that mutations of this nature do not lead to EGFR addiction. The reason for this 
remains speculative but suggests that the primary role of EGFR in GBM may not be tumor 
proliferation or survival but some other important biological function that supports, but is 
not essential to, GBM growth. A recent paper showing that inactive EGFR has a critical role 
in upregulating glucose transport highlights other unanticipated roles for this receptor 
(Weihua et al., 2008). Importantly inhibition of EGFR does not block this activity, rather 
EGFR needed to be removed from the cell surface. This result suggests at least one 
mechanism by which the presence of inactive EGFR may contribute to GBM development in 
www.intechopen.com
 
Advances in the Development of EGFR Targeted Therapies for the Treatment of Glioblastoma 35 
a non-critical manner. Indeed, we have very recently shown that de2-7 EGFR has a role in 
regulating GBM response to low glucose (Cvrljevic et al, in press). 
EGFR antibodies do not have any efficacy in colon cancer in patients containing mutations 
in Ras or Raf (Laurent-Puig et al., 2009). While mutations in these molecules are 
comparatively rare in GBM (McLendon et al., 2008), and thus cannot be used to stratify 
patients, the pathways associated with Ras/Raf can be activated by other RTKs on the cell 
surface. The activation of Ras/Raf by these RTKs might cause de novo resistance to EGFR 
therapeutics. Raf can be targeted directly by TKIs already in the clinic, however Ras cannot 
be inhibited by this approach. However, the signalling of both kinases can be targeted by 
blocking downstream targets such as ERK and MEK (Pratilas & Solit, 2010). If the toxicity 
issues can be managed, targeting these kinases in combination with EGFR inhibitors is a 
logical next step in GBM. This is not a problem in NSCLC as EGFR and ras mutations are 
mutually exclusive in this cancer type.  
Recent data suggests that mutations in PI3K may also cause resistance to EGFR antibodies in 
colon cancer (Weickhardt et al., 2010). This is highly relevant to GBM as the PI3K pathway 
appears to be dysregulated in most GBMs through direct mutation of PI3K, the deletion or 
mutation of the negative PI3K regulator PTEN or activation through other RTKs (McLendon 
et al., 2008). Indeed, as discussed above, the absence of PTEN was associated with clinical 
resistance to EGFR TKIs in GBM patients expressing the de2-7 EGFR while responsiveness 
was associated with co-expression of PTEN and de2-7 EGFR. The recent translation of PI3K 
inhibitors into the clinic provides a strategy for overcoming PI3K-mediated resistance to 
EGFR inhibitors. All the evidence suggests that this combinational approach might finally 
unleash the potential of EGFR inhibitors for the treatment of GBM (Fan & Weiss, 2010); once 
again management of toxicity remains as a concern. 
6.2 Combination of EGFR inhibitors with other targeted therapies 
Since most RTKs can activate Ras/Raf and/or PI3K, the dual inhibition of EGFR and 
additional activated RTKs is an obvious therapeutic approach. Stommel et al clearly showed 
that multiple RTKs can be activated in GBM and that these RTKs activate overlapping 
downstream pathways causing resistance to TKIs that only targeting a single RTK (Stommel 
et al., 2007). The RTK c-Met is also commonly activated in GBM through a number of 
mechanisms and also has an important role in angiogenesis (Abounader & Laterra, 2005). 
We recently showed that co-expression of de2-7 EGFR and c-Met in GBM xenografts causes 
therapeutic resistant to single agents directed to either of these RTK. However, the 
combination of EGFR and c-Met inhibitors produced synergistic anti-tumor activity (Pillay 
et al., 2009), confirming that dual inhibition of RTKs is a valid approach in GBM. A number 
of other RTKs have been shown to be activated in GBM including the FGFR family, Axl, 
ErbB2/3/4, EphA2/7, VEGFR2 and PDGFR┙/┚ (Ren et al., 2007; Pillay et al., 2009). Given 
the range of potential RTKs activated in a given patient, the most effective therapeutic 
strategy may have to be determined by screening patient tissues for RTK mutation and/or 
activation (i.e. phosphorylation) before commencing treatment. 
We recently showed that EGFR and Src-family kinases (SFK) are frequently coactivated in 
GBM (Lu et al., 2009). Furthermore, the de2-7 EGFR physically associated with SFKs and 
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this interaction increased tumor growth and invasion. This association was also confirmed 
in clinical samples. Treatment of GBM xenografts with the EGFR antibody mAb 806 and 
dasatinib, a SFK inhibitor, resulted in synergistic anti-tumor activity compared to either 
agent alone (Lu et al., 2009). These results suggest that the combination of EGFR inhibition 
and SFK blockade may be efficacious in GBM. As such, a trial of evaluating the combination 
of erlotinib and dasatinib has commenced in recurrent GBM (Trial No. NCT00609999). 
7. Conclusion 
The seemingly central role of EGFR in GBM biology would suggest that it should be an 
excellent therapeutic target in GBM; clinical trials clearly show that this is not the case when 
EGFR is targeted alone or in combination with standard GBM therapy. The further 
development of EGFR inhibitors in GBM must be underpinned by additional studies into 
the biology of EGFR in this cancer and the identification of signalling events associated with 
resistance to EGFR therapeutics. On-going rational trials using EGFR inhibitors in 
combination with other TKIs are justified, possibly underpinned by some basic stratification 
of patients based on mutations present in tumors. Finally, a prospective study formally 
proving that therapeutic antibodies do actually enter the GBMs and bind target cells would 
be informative. In conclusion, inhibition of the EGFR pathway in GBM is ineffective as a 
therapeutic strategy even when used in combination with current therapies. However, their 
effectiveness in combination with other targeted therapeutics should form the next stage of 
their development as a therapeutic target. 
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